ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global VHH Antibody Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-32A17407
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global VHH Antibody Drugs Market Research Report 2024
BUY CHAPTERS

Global VHH Antibody Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-32A17407
Report
October 2025
Pages:128
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi Company(Ablynx)
ALPHAMAB ONCOLOGY
Legend Biotech

VHH Antibody Drugs Market

The global VHH Antibody Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Nanobody (Nb), also known as VHH (Variable domain of heavy chain of HCAb) antibody or single-domain antibody, is a small antibody molecule. Compared with traditional antibodies, VHH has smaller molecular size, higher stability and easier engineering, and has a wide range of biomedical application potential.
From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
VHH Antibody Drugs leading manufacturers including Janssen Pharmaceuticals, Sanofi Company(Ablynx), Alphamab Oncology, Legend Biotech, etc., dominate supply; the top five capture approximately % of global revenue, with Janssen Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global VHH Antibody Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of VHH Antibody Drugs Market Report

Report Metric Details
Report Name VHH Antibody Drugs Market
Segment by Type
  • Monovalent Nanobody
  • Bivalent Nanobody
  • Bispecific Nanobody
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Janssen Pharmaceuticals, Sanofi Company(Ablynx), Alphamab Oncology, Legend Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the VHH Antibody Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the VHH Antibody Drugs Market report?

Ans: The main players in the VHH Antibody Drugs Market are Janssen Pharmaceuticals, Sanofi Company(Ablynx), Alphamab Oncology, Legend Biotech

What are the Application segmentation covered in the VHH Antibody Drugs Market report?

Ans: The Applications covered in the VHH Antibody Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the VHH Antibody Drugs Market report?

Ans: The Types covered in the VHH Antibody Drugs Market report are Monovalent Nanobody, Bivalent Nanobody, Bispecific Nanobody, Others

1 Study Coverage
1.1 Introduction to VHH Antibody Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global VHH Antibody Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monovalent Nanobody
1.2.3 Bivalent Nanobody
1.2.4 Bispecific Nanobody
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global VHH Antibody Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global VHH Antibody Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global VHH Antibody Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global VHH Antibody Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global VHH Antibody Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global VHH Antibody Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global VHH Antibody Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Monovalent Nanobody Market Size by Manufacturers
3.5.2 Bivalent Nanobody Market Size by Manufacturers
3.5.3 Bispecific Nanobody Market Size by Manufacturers
3.5.4 Others Market Size by Manufacturers
3.6 Global VHH Antibody Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global VHH Antibody Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global VHH Antibody Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global VHH Antibody Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global VHH Antibody Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America VHH Antibody Drugs Sales and Revenue by Type (2020-2031)
6.4 North America VHH Antibody Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America VHH Antibody Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe VHH Antibody Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe VHH Antibody Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe VHH Antibody Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific VHH Antibody Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific VHH Antibody Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific VHH Antibody Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America VHH Antibody Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America VHH Antibody Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America VHH Antibody Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa VHH Antibody Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa VHH Antibody Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa VHH Antibody Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Janssen Pharmaceuticals
11.1.1 Janssen Pharmaceuticals Corporation Information
11.1.2 Janssen Pharmaceuticals Business Overview
11.1.3 Janssen Pharmaceuticals VHH Antibody Drugs Product Models, Descriptions and Specifications
11.1.4 Janssen Pharmaceuticals VHH Antibody Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Janssen Pharmaceuticals VHH Antibody Drugs Sales by Product in 2024
11.1.6 Janssen Pharmaceuticals VHH Antibody Drugs Sales by Application in 2024
11.1.7 Janssen Pharmaceuticals VHH Antibody Drugs Sales by Geographic Area in 2024
11.1.8 Janssen Pharmaceuticals VHH Antibody Drugs SWOT Analysis
11.1.9 Janssen Pharmaceuticals Recent Developments
11.2 Sanofi Company(Ablynx)
11.2.1 Sanofi Company(Ablynx) Corporation Information
11.2.2 Sanofi Company(Ablynx) Business Overview
11.2.3 Sanofi Company(Ablynx) VHH Antibody Drugs Product Models, Descriptions and Specifications
11.2.4 Sanofi Company(Ablynx) VHH Antibody Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Company(Ablynx) VHH Antibody Drugs Sales by Product in 2024
11.2.6 Sanofi Company(Ablynx) VHH Antibody Drugs Sales by Application in 2024
11.2.7 Sanofi Company(Ablynx) VHH Antibody Drugs Sales by Geographic Area in 2024
11.2.8 Sanofi Company(Ablynx) VHH Antibody Drugs SWOT Analysis
11.2.9 Sanofi Company(Ablynx) Recent Developments
11.3 Alphamab Oncology
11.3.1 Alphamab Oncology Corporation Information
11.3.2 Alphamab Oncology Business Overview
11.3.3 Alphamab Oncology VHH Antibody Drugs Product Models, Descriptions and Specifications
11.3.4 Alphamab Oncology VHH Antibody Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Alphamab Oncology VHH Antibody Drugs Sales by Product in 2024
11.3.6 Alphamab Oncology VHH Antibody Drugs Sales by Application in 2024
11.3.7 Alphamab Oncology VHH Antibody Drugs Sales by Geographic Area in 2024
11.3.8 Alphamab Oncology VHH Antibody Drugs SWOT Analysis
11.3.9 Alphamab Oncology Recent Developments
11.4 Legend Biotech
11.4.1 Legend Biotech Corporation Information
11.4.2 Legend Biotech Business Overview
11.4.3 Legend Biotech VHH Antibody Drugs Product Models, Descriptions and Specifications
11.4.4 Legend Biotech VHH Antibody Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Legend Biotech VHH Antibody Drugs Sales by Product in 2024
11.4.6 Legend Biotech VHH Antibody Drugs Sales by Application in 2024
11.4.7 Legend Biotech VHH Antibody Drugs Sales by Geographic Area in 2024
11.4.8 Legend Biotech VHH Antibody Drugs SWOT Analysis
11.4.9 Legend Biotech Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 VHH Antibody Drugs Industry Chain
12.2 VHH Antibody Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 VHH Antibody Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 VHH Antibody Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 VHH Antibody Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global VHH Antibody Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Sanofi Company(Ablynx)
ALPHAMAB ONCOLOGY
Legend Biotech
List of Tables
 Table 1. Global VHH Antibody Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global VHH Antibody Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global VHH Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global VHH Antibody Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global VHH Antibody Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global VHH Antibody Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global VHH Antibody Drugs Sales by Region (2020-2025) & (K Units)
 Table 8. Global VHH Antibody Drugs Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global VHH Antibody Drugs Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global VHH Antibody Drugs Sales Share by Manufacturers (2020-2025)
 Table 12. Global VHH Antibody Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global VHH Antibody Drugs Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global VHH Antibody Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VHH Antibody Drugs as of 2024)
 Table 16. Global VHH Antibody Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global VHH Antibody Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers VHH Antibody Drugs Manufacturing Base and Headquarters
 Table 19. Global VHH Antibody Drugs Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global VHH Antibody Drugs Sales by Type (2020-2025) & (K Units)
 Table 23. Global VHH Antibody Drugs Sales by Type (2026-2031) & (K Units)
 Table 24. Global VHH Antibody Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global VHH Antibody Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global VHH Antibody Drugs ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global VHH Antibody Drugs Sales by Application (2020-2025) & (K Units)
 Table 29. Global VHH Antibody Drugs Sales by Application (2026-2031) & (K Units)
 Table 30. VHH Antibody Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global VHH Antibody Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global VHH Antibody Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global VHH Antibody Drugs ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America VHH Antibody Drugs Growth Accelerators and Market Barriers
 Table 37. North America VHH Antibody Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America VHH Antibody Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe VHH Antibody Drugs Growth Accelerators and Market Barriers
 Table 40. Europe VHH Antibody Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe VHH Antibody Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific VHH Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific VHH Antibody Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific VHH Antibody Drugs Growth Accelerators and Market Barriers
 Table 45. Southeast Asia VHH Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America VHH Antibody Drugs Investment Opportunities and Key Challenges
 Table 47. Central and South America VHH Antibody Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa VHH Antibody Drugs Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa VHH Antibody Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Janssen Pharmaceuticals Corporation Information
 Table 51. Janssen Pharmaceuticals Description and Major Businesses
 Table 52. Janssen Pharmaceuticals Product Models, Descriptions and Specifications
 Table 53. Janssen Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Janssen Pharmaceuticals Sales Value Proportion by Product in 2024
 Table 55. Janssen Pharmaceuticals Sales Value Proportion by Application in 2024
 Table 56. Janssen Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
 Table 57. Janssen Pharmaceuticals VHH Antibody Drugs SWOT Analysis
 Table 58. Janssen Pharmaceuticals Recent Developments
 Table 59. Sanofi Company(Ablynx) Corporation Information
 Table 60. Sanofi Company(Ablynx) Description and Major Businesses
 Table 61. Sanofi Company(Ablynx) Product Models, Descriptions and Specifications
 Table 62. Sanofi Company(Ablynx) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Sanofi Company(Ablynx) Sales Value Proportion by Product in 2024
 Table 64. Sanofi Company(Ablynx) Sales Value Proportion by Application in 2024
 Table 65. Sanofi Company(Ablynx) Sales Value Proportion by Geographic Area in 2024
 Table 66. Sanofi Company(Ablynx) VHH Antibody Drugs SWOT Analysis
 Table 67. Sanofi Company(Ablynx) Recent Developments
 Table 68. Alphamab Oncology Corporation Information
 Table 69. Alphamab Oncology Description and Major Businesses
 Table 70. Alphamab Oncology Product Models, Descriptions and Specifications
 Table 71. Alphamab Oncology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Alphamab Oncology Sales Value Proportion by Product in 2024
 Table 73. Alphamab Oncology Sales Value Proportion by Application in 2024
 Table 74. Alphamab Oncology Sales Value Proportion by Geographic Area in 2024
 Table 75. Alphamab Oncology VHH Antibody Drugs SWOT Analysis
 Table 76. Alphamab Oncology Recent Developments
 Table 77. Legend Biotech Corporation Information
 Table 78. Legend Biotech Description and Major Businesses
 Table 79. Legend Biotech Product Models, Descriptions and Specifications
 Table 80. Legend Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Legend Biotech Sales Value Proportion by Product in 2024
 Table 82. Legend Biotech Sales Value Proportion by Application in 2024
 Table 83. Legend Biotech Sales Value Proportion by Geographic Area in 2024
 Table 84. Legend Biotech VHH Antibody Drugs SWOT Analysis
 Table 85. Legend Biotech Recent Developments
 Table 86. Key Raw Materials Distribution
 Table 87. Raw Materials Key Suppliers
 Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 89. Milestones in Production Technology Evolution
 Table 90. Distributors List
 Table 91. Market Trends and Market Evolution
 Table 92. Market Drivers and Opportunities
 Table 93. Market Challenges, Risks, and Restraints
 Table 94. Research Programs/Design for This Report
 Table 95. Key Data Information from Secondary Sources
 Table 96. Key Data Information from Primary Sources


List of Figures
 Figure 1. VHH Antibody Drugs Product Picture
 Figure 2. Global VHH Antibody Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Monovalent Nanobody Product Picture
 Figure 4. Bivalent Nanobody Product Picture
 Figure 5. Bispecific Nanobody Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global VHH Antibody Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Other
 Figure 11. VHH Antibody Drugs Report Years Considered
 Figure 12. Global VHH Antibody Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 14. Global VHH Antibody Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global VHH Antibody Drugs Revenue Market Share by Region (2020-2031)
 Figure 16. Global VHH Antibody Drugs Sales (2020-2031) & (K Units)
 Figure 17. Global VHH Antibody Drugs Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 18. Global VHH Antibody Drugs Sales Market Share by Region (2020-2031)
 Figure 19. Top 5 and Top 10 Manufacturers VHH Antibody Drugs Sales Volume Market Share in 2024
 Figure 20. Global VHH Antibody Drugs Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. Monovalent Nanobody Revenue Market Share by Manufacturer in 2024
 Figure 23. Bivalent Nanobody Revenue Market Share by Manufacturer in 2024
 Figure 24. Bispecific Nanobody Revenue Market Share by Manufacturer in 2024
 Figure 25. Others Revenue Market Share by Manufacturer in 2024
 Figure 26. Global VHH Antibody Drugs Sales Market Share by Type (2020-2031)
 Figure 27. Global VHH Antibody Drugs Revenue Market Share by Type (2020-2031)
 Figure 28. Global VHH Antibody Drugs Sales Market Share by Application (2020-2031)
 Figure 29. Global VHH Antibody Drugs Revenue Market Share by Application (2020-2031)
 Figure 30. North America VHH Antibody Drugs Sales YoY (2020-2031) & (K Units)
 Figure 31. North America VHH Antibody Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. North America Top 5 Manufacturers VHH Antibody Drugs Sales Revenue (US$ Million) in 2024
 Figure 33. North America VHH Antibody Drugs Sales Volume (K Units) by Type (2020- 2031)
 Figure 34. North America VHH Antibody Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 35. North America VHH Antibody Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 36. North America VHH Antibody Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 37. US VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 38. Canada VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 39. Mexico VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 40. Europe VHH Antibody Drugs Sales YoY (2020-2031) & (K Units)
 Figure 41. Europe VHH Antibody Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 42. Europe Top 5 Manufacturers VHH Antibody Drugs Sales Revenue (US$ Million) in 2024
 Figure 43. Europe VHH Antibody Drugs Sales Volume (K Units) by Type (2020-2031)
 Figure 44. Europe VHH Antibody Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 45. Europe VHH Antibody Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 46. Europe VHH Antibody Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Germany VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. France VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. U.K. VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Italy VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. Russia VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific VHH Antibody Drugs Sales YoY (2020-2031) & (K Units)
 Figure 53. Asia-Pacific VHH Antibody Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Asia-Pacific Top 8 Manufacturers VHH Antibody Drugs Sales Revenue (US$ Million) in 2024
 Figure 55. Asia-Pacific VHH Antibody Drugs Sales Volume (K Units) by Type (2020- 2031)
 Figure 56. Asia-Pacific VHH Antibody Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 57. Asia-Pacific VHH Antibody Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 58. Asia-Pacific VHH Antibody Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 59. Indonesia VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 60. Japan VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 61. South Korea VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 62. China Taiwan VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 63. India VHH Antibody Drugs Revenue (2020-2031) & (US$ Million)
 Figure 64. Central and South America VHH Antibody Drugs Sales YoY (2020-2031) & (K Units)
 Figure 65. Central and South America VHH Antibody Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 66. Central and South America Top 5 Manufacturers VHH Antibody Drugs Sales Revenue (US$ Million) in 2024
 Figure 67. Central and South America VHH Antibody Drugs Sales Volume (K Units) by Type (2021-2031)
 Figure 68. Central and South America VHH Antibody Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 69. Central and South America VHH Antibody Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 70. Central and South America VHH Antibody Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 71. Brazil VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 72. Argentina VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 73. Middle East, and Africa VHH Antibody Drugs Sales YoY (2020-2031) & (K Units)
 Figure 74. Middle East and Africa VHH Antibody Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 75. Middle East and Africa Top 5 Manufacturers VHH Antibody Drugs Sales Revenue (US$ Million) in 2024
 Figure 76. Middle East and Africa VHH Antibody Drugs Sales Volume (K Units) by Type (2021-2031)
 Figure 77. South America VHH Antibody Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 78. Middle East and Africa VHH Antibody Drugs Sales Volume (K Units) by Application (2020-2031)
 Figure 79. Middle East and Africa VHH Antibody Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 80. GCC Countries VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 81. Turkey VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 82. Egypt VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 83. South Africa VHH Antibody Drugs Revenue (2020-2025) & (US$ Million)
 Figure 84. VHH Antibody Drugs Industry Chain Mapping
 Figure 85. Regional VHH Antibody Drugs Manufacturing Base Distribution (%)
 Figure 86. Global VHH Antibody Drugs Production Market Share by Region (2020-2031)
 Figure 87. VHH Antibody Drugs Production Process
 Figure 88. Regional VHH Antibody Drugs Production Cost Structure
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global Construction of VHH antibody library Market Research Report 2024
Global Nanobody Sequence Library Market Research Report 2024
Global VHH Nanobodies Market Research Report 2024
Global Single Domain Antibody sdAbs Drugs Market Research Report 2024
Global Single Domain Antibody Library Service Market Research Report 2024
Global Nanobody Discovery Service Market Research Report 2024
Global Single Domain Heavy Chain Antibody Market Research Report 2025
XDH Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Custom Nanobody Service Market Research Report 2025
Global Research Grade Antibodies Market Research Report 2024
NeuN Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Molecule Antibodies Market Insights Forecast to 2030
B220 Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
B7 H3 Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Camelid VHH Antibody Market Research Report 2024
Vimentin Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti GFP Nanobody Market Research Report 2024
Global Nanobody Drug Market Research Report 2024
Global Myoglobin Antibody Market Research Report 2024
Global BAG1 Antibody Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions